Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Adams

Family Medicine Springfield, MO Medical Doctor

NPI 1245363993 CMS profile 101316

3525 S. National Ave, #101, Springfield, MO 65807

Open in the dashboard

General payments

$636,342

1,366 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Adams of Springfield, MO is reported in the CMS Open Payments database as having received $636,342 across 1,366 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59,503 196
2024 General $153,050 282
2023 General $132,866 259
2022 General $88,203 201
2021 General $67,793 155
2020 General $49,205 96
2019 General $85,722 177

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Adams
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Stephen Adams were reported at $59,503. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Stephen Adams Family Medicine median Middle half National median
2019 $85,722 $150 $41–$543 $163
2020 $49,205 $120 $32–$415 $114
2021 $67,793 $137 $35–$551 $132
2022 $88,203 $137 $37–$512 $149
2023 $132,866 $149 $42–$545 $160
2024 $153,050 $156 $44–$560 $164
2025 $59,503 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $539,394 651 payments
  2. Gilead Sciences, Inc. $89,128 313 payments
  3. AbbVie, Inc. $944 43 payments
  4. Merck Sharp & Dohme Corporation $939 50 payments
  5. Otsuka America Pharmaceutical, Inc. $813 41 payments
  6. Janssen Biotech, Inc. $663 57 payments
  7. Neurocrine Biosciences, Inc. $463 20 payments
  8. Napo Pharmaceuticals Inc $442 24 payments
  9. EMD Serono, Inc. $414 22 payments
  10. Vanda Pharmaceuticals Inc. $406 16 payments
  11. Other $2,737 129 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $496,311 197 payments
  2. Travel and Lodging $96,621 208 payments
  3. Food and Beverage $28,360 946 payments
  4. Consulting Fee $14,580 6 payments
  5. Education $470 9 payments
Products named General payments · program years 2019–2025
  1. DOVATO $398,207 399 payments
  2. APRETUDE Hiv $112,961 128 payments
  3. Biktarvy $66,904 112 payments
  4. APRETUDE Hiv $20,966 35 payments
  5. Sunlenca $3,118 5 payments
  6. CABENUVA $1,243 29 payments
  7. SYMTUZA $1,142 62 payments
  8. TIVICAY $976 10 payments
  9. VRAYLAR $816 36 payments
  10. PIFELTRO $782 46 payments
  11. Other $8,131 445 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

4,454

Median for Family Practice: 1,826

Drug cost

$4,254,658

Median for Family Practice: $120,094

Branded share of claims

40.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 376 $1,497,165
Dovato Dolutegravir Sodium/Lamivudine Brand 222 $689,281
Serostim Somatropin Brand 23 $474,143
Cabenuva Cabotegravir/Rilpivirine Brand 66 $436,475
Tivicay Dolutegravir Sodium Brand 161 $426,698
Descovy Emtricitabine/Tenofov Alafenam Brand 74 $158,464
Mytesi Crofelemer Brand 47 $116,463
Pifeltro Doravirine Brand 55 $93,910
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 14 $56,309
Prezcobix Darunavir/Cobicistat Brand 23 $56,137

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DOVATO
$83,930 222 —
APRETUDE
$42,072 — —
Biktarvy
$21,126 376 —
VRAYLAR
$333 — —
INGREZZA
$151 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

1,366 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record